Cocrystal Pharma completes patient enrollment in phase 2a study evaluating CC-31244
Cocrystal Pharma announced completion of patient enrollment in its Phase 2a clinical study evaluating CC-31244 for the ultra-short treatment of hepatitis C virus-infected individuals. The study is designed to evaluate safety, tolerability and preliminary efficacy of CC-31244 with Gilead’s Epclusa®. September 20, 2018